The Current Practice of Screening, Prevention, and Treatment of Androgen-Deprivation-Therapy Induced Osteoporosis in Patients with Prostate CancerReportar como inadecuado




The Current Practice of Screening, Prevention, and Treatment of Androgen-Deprivation-Therapy Induced Osteoporosis in Patients with Prostate Cancer - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Journal of OncologyVolume 2012 2012, Article ID 958596, 7 pages

Clinical Study

Division of Medical Oncology, Department of Medicine, Juravinski Cancer Centre, McMaster University Hamilton Health Sciences, Hamilton, ON, Canada L8V 5C2

Division of Rheumatology, Department of Medicine, St. Joseph Hospital, McMaster University Hamilton Health Sciences, Hamilton, ON, Canada L8N 1Y2

Division of Geriatric Medicine, Department of Medicine, University of Toronto, Toronto, ON, Canada M5S 2E9

Division of Urology, Department of Surgery, St. Joseph Hospital, McMaster University Hamilton Health Sciences, Hamilton, ON, Canada L8N 1Y2

Department of Medicine, McMaster University Hamilton Health Sciences, Hamilton, ON, Canada L8S 4K1

Division of Radiation Oncology, Department of Oncology, Juravinski Cancer Centre, McMaster University Hamilton Health Sciences, Hamilton, ON, Canada L8V 5C2

Division of Medicine, Department of Medicine, McMaster University Hamilton Health Sciences, Hamilton, ON, Canada L8N 1Y2

Division of Geriatric Medicine, Department of Medicine, McMaster University Hamilton Health Sciences, Hamilton, ON, Canada L8S 4K1

Received 19 January 2012; Accepted 14 February 2012

Academic Editor: M. Roach

Copyright © 2012 Humaid O. Al-Shamsi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction. ADT is used in the management of locally advanced and metastatic disease. The detrimental effect of ADT on bone density is well documented. This study assesses care gaps in screening, prevention and treatment of osteoporosis among prostate cancer patients. Methods. We conducted a retrospective cohort study for patients diagnosed with non-metastatic prostate cancer on ADT. Charts from a tertiary oncology center were assessed for utilization of DXA scan, prescription of calcium, vitamin D, calcitonin and bisphosphonates.Bivariate analysis was used to determine the effect of patient characteristics and likelihood for osteoporosis screening. Results. 149 charts were reviewed, with 3-year mean follow-up. 58.8% of men received a baseline DXA, of which 20.3% had a repeat DXA within their follow-up periods.In all, 28% were appropriately screened and managed for osteoporosis received repeat DXA, bisphosphonate. In bivariate analysis, the number of ADT injections which correlate with the duration of androgen suppression was significantly associated with the number of DXA scans. Conclusions. Our study found a care gap in the screening, prevention, and treatment of osteoporosis in this population. Patients receiving the most ADT injections were more likely to be screened. Our results suggest healthcare providers treating prostate cancer are insufficiently screening and treating this susceptible population. We suggest baseline measurement of BMD at the initiation of ADT with periodic reassessment during therapy.





Autor: Humaid O. Al-Shamsi, Arthur N. Lau, Kartika Malik, Abdulaziz Alamri, George Ioannidis, Tom Corbett, J. D. Adachi, and Alexa

Fuente: https://www.hindawi.com/



DESCARGAR PDF




Documentos relacionados